Erez MBA - Dr Reddys CEO Council

RDDA Stock  EUR 14.30  0.10  0.70%   

Insider

Erez MBA is CEO Council of Dr Reddys Laboratories
Age 55
Phone91 40 4900 2900
Webhttps://www.drreddys.com

Dr Reddys Management Efficiency

The company has return on total asset (ROA) of 0.0949 % which means that it generated a profit of $0.0949 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1772 %, meaning that it generated $0.1772 on every $100 dollars invested by stockholders. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities.
Dr Reddys Laboratories has accumulated 5.75 B in total debt with debt to equity ratio (D/E) of 23.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Dr Reddys Laboratories has a current ratio of 1.85, which is within standard range for the sector. Debt can assist Dr Reddys until it has trouble settling it off, either with new capital or with free cash flow. So, Dr Reddys' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dr Reddys Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RDDA to invest in growth at high rates of return. When we think about Dr Reddys' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Aidan MurphyIpsen SA
57
Wafaa MamilliZoetis Inc
56
Thomas CastellanoCatalent
43
Pablo MoraSwedish Orphan Biovitrum
55
Ryuichi KiyamaShionogi Co
N/A
Karen SantiagoCatalent
52
Aymeric ChatelierIpsen SA
54
Henrik StenqvistSwedish Orphan Biovitrum
55
Armin MDSwedish Orphan Biovitrum
65
Yosuke AkitaEisai Co
58
Sven DethlefsTeva Pharmaceutical Industries
54
Francois GarnierIpsen SA
61
Steven EsqCatalent
60
Yoshimasa KyokawaShionogi Co
N/A
Steven FrankZoetis Inc
N/A
Stephan GagneIpsen SA
N/A
Nadeem SarwarEisai Co
N/A
Mark SabagTeva Pharmaceutical Industries
52
John KellerShionogi Co
58
Kare SchultzTeva Pharmaceutical Industries
62
Kevin MannixTeva Pharmaceutical Industries
N/A
Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. DR REDDYS operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 21966 people. Dr Reddys Laboratories (RDDA) is traded on Frankfurt Exchange in Germany and employs 24,795 people.

Management Performance

Dr Reddys Laboratories Leadership Team

Elected by the shareholders, the Dr Reddys' board of directors comprises two types of representatives: Dr Reddys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RDDA. The board's role is to monitor Dr Reddys' management team and ensure that shareholders' interests are well served. Dr Reddys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dr Reddys' outside directors are responsible for providing unbiased perspectives on the board's policies.
Parag Agarwal, CFO Council
Sanjay BTech, Global VP
Erez MBA, CEO Council
Gunupati BE, MD CoChairman
MS BTech, Chairman Council
MBA MBA, CEO Council
Deepak MBA, CEO Council

RDDA Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dr Reddys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in RDDA Stock

When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.